Design of Cyclodextrin-Based Sustained Release Formulation of Benzbromarone: A Step toward Improved Management of Gout
Ars Pharmaceutica (Internet) · 20.06.2026 · 67 (3) · 284-298
DOI: 10.30827/ars.v67i3.35659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ars Pharmaceutica (Internet), online erschienen am 20.06.2026. Verfasst von Eknath D. Ahire und 4 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Introduction
The current study aimed to enhance the bioavailability of benzbromarone through the creation of a sustained-release (SR) tablet, employing β-cyclodextrin complexation to promote solubility and diminish protein binding. Benzbromarone is a uricosuric medication that works by blocking the URAT1 exchanger in the renal proximal tubule. It has low bioavailability since it doesn’t dissolve well in water and binds to proteins strongly.
Methods
The drug-β-cyclodextrin complex was created and made into sustained-release tablets by mixing and matching varying amounts of HPMC K4M and HPMC K100M as matrix-forming polymers. The formulations were tested for pre- and post-compression characteristics, in vitro dissolution, and kinetic modeling.
Results
Formulation F6, which had 10% total polymer concentration (5% HPMC K4M and 5% HPMC K100M), had the best physicochemical qualities and released the most medication for 24 hours (95.71%). Kinetic modeling showed that the release followed zero-order kinetics (R² = 0.9979) and was in line with the Higuchi diffusion model (R² = 0.9784), which points to a diffusion-controlled mechanism.
Conclusion
The results show that β-cyclodextrin considerably improves the solubility and release properties of benzbromarone, making it a viable sustained-release formulation for better gout treatment.
Zitieren
APA
Ahire, E. D., Pawar, S. S., Kshirsagar, S. J., Mogal, R. T., & Surana, K. R. (2026). Design of Cyclodextrin-Based Sustained Release Formulation of Benzbromarone: A Step toward Improved Management of Gout. Ars Pharmaceutica (Internet), 67(3), 284-298. https://doi.org/10.30827/ars.v67i3.35659
Vancouver
Ahire ED, Pawar SS, Kshirsagar SJ, Mogal RT, Surana KR. Design of Cyclodextrin-Based Sustained Release Formulation of Benzbromarone: A Step toward Improved Management of Gout. Ars Pharmaceutica (Internet). 2026;67(3):284-298. doi:10.30827/ars.v67i3.35659
BibTeX
@article{Ahire2026,
author = {Ahire, Eknath D. and Pawar, Sanket S. and Kshirsagar, Sanjay J. and Mogal, Rajendra T. and Surana, Khemchand R.},
title = {Design of Cyclodextrin-Based Sustained Release Formulation of Benzbromarone: A Step toward Improved Management of Gout},
journal = {Ars Pharmaceutica (Internet)},
year = {2026},
volume = {67},
number = {3},
pages = {284--298},
doi = {10.30827/ars.v67i3.35659}
}
EUVIMED